Article
Medicine, General & Internal
Sara Torresan, Gaia Zussino, Francesco Cortiula, Alessandro Follador, Gianpiero Fasola, Rossano Girometti, Lorenzo Cereser
Summary: We report a case of radiation recall pneumonitis followed by immune-checkpoint inhibitor-induced pneumonitis in a patient with non-small cell lung cancer. This case emphasizes the importance of considering radiation recall pneumonitis in the differential diagnosis of lung consolidation during immunotherapy and suggests that it may anticipate more extensive immune-checkpoint inhibitor-induced pneumonitis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Xiaotong Lu, Jianyang Wang, Tao Zhang, Zongmei Zhou, Lei Deng, Xin Wang, Wenqing Wang, Wenyang Liu, Wei Tang, Zhijie Wang, Jie Wang, Wei Jiang, Nan Bi, Luhua Wang
Summary: This retrospective study investigated the risk of treatment-related pneumonitis in Chinese lung cancer patients who received thoracic radiotherapy (TRT) followed by immune checkpoint inhibitor (ICI) therapy. The results showed that the occurrence of pneumonitis was relatively high, but manageable, and dosimetric parameters could improve the prediction of radiation recall pneumonitis.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Min Wang, Shuhui Xu, Hui Zhu
Summary: This report presents a rare case of double pneumonitis (RP and RRP) in a patient with non-small lung cancer (NSCLC), with RP occurring at 3 months and RRP induced by anti-PD-1 sintilimab at 10 months after radiotherapy. This case draws attention to the identification of immune or radiation pneumonitis, its potential mechanism, and the treatment strategy for RRP.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Francois Cousin, Colin Desir, Selma Ben Mustapha, Carole Mievis, Philippe Coucke, Roland Hustinx
Summary: This study found a high incidence of radiation recall pneumonitis (RRP) at 18.8% among patients with advanced lung cancer treated with immune checkpoint inhibitors. No risk factors for RRP were identified, but an association between RRP and ICI-related pneumonitis was noted.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Respiratory System
Xianghua Ye, Jinsong Yang, Justin Stebbing, Ling Peng
Summary: Background radiation recall pneumonitis (RRP) is a rare but severe complication associated with previous irradiated fields, which can be triggered by chemotherapy, targeted drugs, and immune checkpoint inhibitors. This case report highlights the increased risk of RRP in patients receiving immunotherapy after prior radiation therapy.
BMC PULMONARY MEDICINE
(2022)
Article
Health Care Sciences & Services
Marek Konkol, Maciej Bryl, Marek Fechner, Krzysztof Matuszewski, Pawel Sniatala, Piotr Milecki
Summary: Radiation-induced lung injury is a significant toxicity in thoracic radiotherapy. This study aimed to establish a quantitative grading method by analyzing the changes in lung tissue density using CT scans. The results confirmed a dose-response effect and identified clinical factors that correlated with the degree of lung injury.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Masayuki Okumura, Hidehiro Hojo, Masaki Nakamura, Takashi Hiyama, Naoki Nakamura, Sadamoto Zenda, Atsushi Motegi, Yasuhiro Hirano, Shun-Ichiro Kageyama, Raturi Vijay Parshuram, Takeshi Fujisawa, Hirofumi Kuno, Tetsuo Akimoto
Summary: This study investigated the risk of radiation pneumonitis (RP) after palliative radiotherapy in cancer patients with interstitial lung disease. The results showed that ILD pattern was a significant predictive factor for severe RP. Careful administration of radiotherapy involving a lung field to ILD patients is recommended, and evaluation of the ILD pattern on pretreatment CT images may be helpful in treatment decisions.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Lucheng Zhu, Changlin Zou, Zhanchun Zhang, Jianfang Wang, Li Yang, Chuangzhou Rao, Zhiping Yang, Jiafeng Liang, Bing Xia, M. A. Shenglin
Summary: This study aims to explore the safety and efficacy of concurrent almonertinib, a new third-generation EGFR-TKI, with radiotherapy in locally advanced EGFR-mutated NSCLC patients. The primary endpoint is the incidence of grade >= 3 radiation pneumonitis within 6 months post-radiotherapy, with secondary endpoints including local control rate, progression-free survival, and overall survival. The trial protocol has been approved by the Ethics committee of Hangzhou cancer hospital.
Article
Oncology
Matthew R. McFarlane, Kimberly A. Hochstedler, Anna M. Laucis, Yilun Sun, Aulina Chowdhury, Martha M. Matuszak, James Hayman, Derek Bergsma, Thomas Boike, Larry Kestin, Benjamin Movsas, Inga Grills, Michael Dominello, Robert T. Dess, Caitlin Schonewolf, Daniel E. Spratt, Lori Pierce, Peter Paximadis, Shruti Jolly, Matthew Schipper
Summary: This study analyzed pneumonitis risk after radiation therapy for lung cancer using a large, prospective dataset. Comorbidity burden, smoking status, and dosimetric parameters were incorporated in an integrated risk model to guide clinicians in assessing pneumonitis risk in individual patients.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Yu Chen, Xinchao Liu, Zhaoqin Huang, Kaikai Zhao, Yao Wang, Fei Ren, Jinming Yu, Xiangjiao Meng
Summary: This retrospective study evaluated the safety of thoracic radiotherapy (TRT) after programmed death 1/programmed death ligand 1 (PD-(L)1) inhibitor treatment in lung cancer patients. The results showed that pulmonary emphysema and lung V20 were independent risk factors for symptomatic treatment-related pneumonitis associated with this sequential combination.
Article
Pharmacology & Pharmacy
Bing Li, Ge Ren, Wei Guo, Jiang Zhang, Sai-Kit Lam, Xiaoli Zheng, Xinzhi Teng, Yunhan Wang, Yang Yang, Qinfu Dan, Lingguang Meng, Zongrui Ma, Chen Cheng, Hongyan Tao, Hongchang Lei, Jing Cai, Hong Ge
Summary: This study investigates the impact of lung function on radiation pneumonitis prediction using a dual-omics analysis method, and finds that dual-omics features from different lung functional regions can improve the prediction of radiation pneumonitis for lung cancer patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Li Li, Shanshan Tang, Jiani C. Yin, Lihua Dong, Zhe Yang, Yueping Liu, Jie Ma, Pengyu Chang, Jiaohui Pang, Hua Bao, Dianbin Mu, Xiaoli Zheng, Reyida Aishajiang, Kewen He, Shaotong Zhang, Meng Ni, Xue Wu, Xiaonan Wang, Yang Shao, Jun Wang, Hong Ge, Jinming Yu, Shuanghu Yuan
Summary: By examining the mutational landscape of a large cohort of limited-stage SCLC, we identified novel molecular predictors of survival and radiation-induced thoracic toxicity (RITT). Our findings also implicate several key molecular pathways, including the MAPK/ERK and DNA damage repair pathways, in the regulation of dCRT response.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Bing Li, Xiaoli Zheng, Jiang Zhang, Saikit Lam, Wei Guo, Yunhan Wang, Sunan Cui, Xinzhi Teng, Yuanpeng Zhang, Zongrui Ma, Ta Zhou, Zhaoyang Lou, Lingguang Meng, Hong Ge, Jing Cai
Summary: The study evaluates the effectiveness of features obtained from proposed incremental-dose-interval-based lung subregion segmentation for predicting grade >= 2 acute radiation pneumonitis (ARP) in lung cancer patients. Results show that features from lung subregions outperform those from the whole lung in predicting ARP, especially when using dosiomics or combined radiomics-dosiomics features. This improved model performance could enhance clinical management and patient quality of life.
Article
Medicine, Research & Experimental
Jingshu Meng, Yan Li, Chao Wan, Yajie Sun, Xiaomeng Dai, Jing Huang, Yan Hu, Yanan Gao, Bian Wu, Zhanjie Zhang, Ke Jiang, Shuangbing Xu, Jonathan F. Lovell, Yu Hu, Gang Wu, Honglin Jin, Kunyu Yang
Summary: The study highlights the importance of targeting senescence-like characteristics in cancer-associated fibroblasts to enhance radiosensitivity of non-small cell lung cancer cells, as well as alleviate radiation-induced pulmonary fibrosis.
Article
Oncology
Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E. Gaspar, John Heymach, James Bonner, Charles Kuzma, Saiama Waqar, William Petty, Thomas E. Stinchcombe, Jeffrey D. Bradley, Everett Vokes
Summary: A randomized trial found that 45-Gy twice-daily radiotherapy is still the standard treatment for limited-stage small-cell lung cancer, despite the fact that most patients receive higher-dose once-daily regimens in clinical practice. This study provides the most robust information available to guide the choice of thoracic radiotherapy regimen for patients with limited-stage small-cell lung cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)